Ophthalmic Therapeutics/Drugs Market Is Projected To Grow Rapidly Due To Increase In R&D For The Development Of Novel Entityare Till 2025: Grand View Research, Inc.
The
global ophthalmic therapeutics/drugs market is expected to reach USD 35.7
billion by 2025, according to a new report by Grand View Research, Inc.
Increase in funding by public and private bodies for conducting research on
ocular disorders with the presence of strong emerging pipeline drugs are some
of the factors responsible for the growth of ophthalmic therapeutics market.
For instance, the recent approval of Zerviate (cetirizine) for the treatment of
allergic conjunctivitis in 2017 and Humira (adalimumab) and Xiidra
(lifitegrast) in 2016 as ophthalmic solutions for the treatment of uveitis and
dry eyes are expected to boost the market growth.
Numerous
ongoing public-private partnership agreements in the pharmaceutical industry
for the development of novel therapeutics are expected to provide this market
with lucrative growth opportunities. In the recent years, a number of
highly-effective and safe agents have emerged for the treatment of fungal
ophthalmic diseases. Natamycin, amphotericin B, clotrimazole, are some of the
most promising therapeutics present in the market. For instance, in October
2016, Santen Pharmaceuticals, Foundation for Biomedical Research and Innovation
(FBRI), and RIKEN announced a research collaboration to develop new treatments
for retinal diseases such as age-related macular degeneration and retinitis
pigmentosa.
U.S
ophthalmic therapeutics/drug market, by class, 2014 - 2025 (USD Billion)
Browse full
research report on Ophthalmic Therapeutics/Drugs Market: http://www.grandviewresearch.com/industry-analysis/ophthalmic-therapeutics-drug-market
Further key
findings from the report suggest:
- Antiallergy is the largest segment owing to the
increasing incidence of ocular infections, high prescription rate of antiallergy
agents, and presence of a wide product portfolio
- Retinal disorders segment dominated the market
in 2016 due to increasing prevalence of age-related macular degenerations
and diabetic retinopathy, its subtypes
- The eye drops segment is anticipated to
dominate the market in 2016. It is considered as the most preferred dosage
form due to associated benefits such as easy assimilation, target-specific
action, and faster recovery
- Over-the-Counter (OTC) held the largest share
in 2016 due to its low cost and increasing preference of OTC over
prescription drugs
- North America dominated the market in 2016
owing to factors such as the increase in demand for ophthalmic solutions
for the treatment of glaucoma and dry eyes in this region.
- Asia Pacific is anticipated to be the fastest
growing region with a lucrative CAGR during the forecast period due to
rising disposable income, presence of a large population base, and growing
awareness programs by various organizations.
- Some of the key players in this industry are
Allergan; Aerie Pharmaceuticals, Inc.; Pfizer Inc.; Valeant
Pharmaceuticals International, Inc.; Bayer AG; Genentech, Inc.; Novartis
AG; Regeneron Pharmaceuticals, Inc.; Shire; and Santen Pharmaceutical Co.,
Ltd.
Browse more
reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global ophthalmic
therapeutics/drugs market on the basis of class, disease, dosage form, product,
and region:
Drug Class
Outlook (Revenue, USD Million; 2014 - 2025)
- Antiallergy
- Anti-Vascular
Endothelial Growth Factor (Anti-VEGF) agents
- Anti-inflammatory
- Nonsteroidal
drugs
- Steroidal
drugs
- Antiglaucoma
- Others
Disease
Outlook (Revenue, USD Million; 2014 - 2025)
- Dry Eye
- Allergies
- Glaucoma
- Inflammation/Infection
- Retinal
Disorders
- Uveitis
- Others
Dosage form
Outlook (Revenue, USD Million; 2014 - 2025)
- Gels
- Eye
solutions
- Capsules
& Tablets
- Eye
drops
- Ointments
Product
Outlook (Revenue, USD Million; 2014 - 2025)
- Prescription
drugs
- OTC
drugs
Regional
Outlook (Revenue, USD Million; 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- Middle East
& Africa
- South
Africa
Access
Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-ophthalmic-therapeutics-drug-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment